Saline that starts at $1.07 ends up costing about 90 times more

Eric Palmer The New York Times recently found out that different patients treated in a recent food-poisoning event paid prices that ranged over hundreds of dollars for basic IV saline ...

Mylan Confirms Approval of sANDA for Bupropion

mia.burns Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg -Company continues to supply product to U.S. market – PITTSBURGH, ...

Report: Amgen balks at $9.5B Onyx bid after data dispute

John Carroll Quoting sources, Bloomberg says that Amgen is now pushing for a lower price after Onyx refused to hand over data from an ongoing study of the blood-cancer drug Kyprolis ...

Shire and Santaris Extend Alliance

mia.burns Shire and Santaris extend their strategic alliance to discover and develop LNA-drugs in the rare genetic disease field HOERSHOLM, Denmark and SAN DIEGO, Aug. 23, ...

Amgen bags Onyx Pharma in $10.4B buyout deal

John Carroll Amgen was the first company to make it to the auction block for Onyx Pharmaceuticals. And in the end, it was the only serious bidder left at the table.  FierceBiotech ...

Qsymia scripts moving up solidly as dust settles in boardroom

Carly Helfand According to a research note from analyst Michael Yee at RBC Capital Markets, total Qsymia prescriptions for the weight-loss drug are up 7% week-over-week to 10,019, with ...

Abbott Completes Acquisition of IDEV Technologies

mia.burns Date: August 21, 2013  Abbott Park, Illinois (NYSE: ABT) — Abbott today announced that it has completed its acquisition of IDEV Technologies, a privately held company ...

3-D printing creates living tissue cells, holds promise for medical research

Emily Mullin In the last few decades, 3-D printing has become a reality–no longer the stuff of science fiction. It's mostly known for its capability to create prototypes, ...

Indian authorities confirm closer look at Ranbaxy operations

Eric Palmer In the U.S., the furor over Ranbaxy Laboratories' misdeeds has largely settled down, but the generics drugmaker is having trouble getting past it at home in India. Authorities, ...

Pharmalot… Pharmalittle.. Vacation Time

esilverman And so, Pharmalot friends, we are taking a much-needed break. This is, after all, a time of year when so many are on vacation already, or about to embark on one. ...

GlaxoSmithKline ponders future of Crohn’s disease drug after PhIII flop

John Carroll One of GlaxoSmithKline's late-stage assets for Crohn's disease has failed a Phase III study, pushing the pharma giant to suspend patient recruitment in the ambitious ...

FDA says Mylan’s Wellbutrin generic stacks up to branded drug

Eric Palmer Mylan is the first drugmaker to make it through FDA scrutiny of its generic of antidepressant Wellbutrin XL in a regulatory episode that has reignited debate over the quality ...
Page 4 of 38« First...23456...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS